Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Breast Neoplasms 3Prostatic Neoplasms 2Overweight 2Obesity 2Melanoma 2Substance Withdrawal Syndrome 1Skin Neoplasms 1Kidney Neoplasms 1Glioma 1Glioblastoma 1Chronic Pain 1Carcinoma, Lobular 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

pembrolizumab 23Nivolumab 22aldesleukin 21Cyclophosphamide 20Ipilimumab 17Interleukin-2 17fludarabine 15fludarabine phosphate 14cemiplimab 12Radiotherapy 7Fluorouracil 7Dacarbazine 6binimetinib 5Vemurafenib 5Temozolomide 5Surgical Procedures, Operative 5Sirolimus 5Radiation 5Biopsy 5Aminolevulinic Acid 5encorafenib 4dabrafenib 4Photochemotherapy 4Educational Status 4trametinib 3sonidegib 3montanide ISA 51 3avelumab 3Tacrolimus 3Sodium Chloride 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Skin Neoplasms × Naltrexone × Clear all
NCT05968690 2025-09-18

Naltrexone and Propranolol Combined With Immunotherapy

Rutgers, The State University of New Jersey

Phase 1 Recruiting
12 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡